-
Indian Journal of Pediatrics Feb 2022
Topics: Bland White Garland Syndrome; Cardiomyopathy, Dilated; Coronary Vessel Anomalies; Humans; Infant; Pulmonary Artery
PubMed: 33905090
DOI: 10.1007/s12098-021-03754-0 -
Cleveland Clinic Journal of Medicine Jun 2002While researchers try to elucidate the origins of idiopathic dilated cardiomyopathy, clinicians continue to face the challenges of identifying and treating the causes of... (Review)
Review
While researchers try to elucidate the origins of idiopathic dilated cardiomyopathy, clinicians continue to face the challenges of identifying and treating the causes of this condition to improve symptoms and survival. We review classification schemes for dilated cardiomyopathy and the current range of diagnostic and therapeutic options and treatment goals.
Topics: Cardiomyopathy, Dilated; Female; Heart Failure; Humans; Incidence; Male; Prognosis; Risk Assessment; Risk Factors; Survival Rate; United States
PubMed: 12061463
DOI: 10.3949/ccjm.69.6.481 -
European Heart Journal Nov 2000
Review
Topics: Cardiomyopathy, Dilated; Molecular Biology; Pedigree
PubMed: 11052854
DOI: 10.1053/euhj.2000.2173 -
Nuclear Medicine Communications Nov 2010Dilated cardiomyopathy (DCM) is characterized by ventricular chamber enlargement and systolic dysfunction with normal ventricular wall thickness. More recent studies... (Review)
Review
Dilated cardiomyopathy (DCM) is characterized by ventricular chamber enlargement and systolic dysfunction with normal ventricular wall thickness. More recent studies have shown that the coronary microcirculation may be directly affected in cardiomyopathies. Left ventricular regional myocardial perfusion, wall motion, and metabolism abnormalities are often present in patients with DCM. These data support the possibility that myocardial ischemia may play an important role in the development of DCM and have important prognostic value in patients with DCM. We need to pay attention to the assessment of myocardial blood flow and myocardial ischemia in patients with DCM. Furthermore, anti-ischemic therapy may improve left ventricular function and clinical outcomes in patients with heart failure resulted from DCM.
Topics: Cardiomyopathy, Dilated; Coronary Circulation; Humans; Myocardial Ischemia; Myocardium; Prognosis
PubMed: 20808261
DOI: 10.1097/MNM.0b013e32833f393f -
Giornale Italiano Di Cardiologia (2006) Jan 2016Dilated cardiomyopathy (DCM) is a relatively rare primary heart muscle disease with genetic or post-inflammatory etiology. In the last decade, the incidence and... (Review)
Review
Dilated cardiomyopathy (DCM) is a relatively rare primary heart muscle disease with genetic or post-inflammatory etiology. In the last decade, the incidence and prevalence of the disease have significantly increased as a consequence of an earlier diagnosis supported by extensive familial screening programs and by the improvement in diagnostic techniques. Moreover, current therapeutic strategies have deeply modified the prognosis of DCM with a dramatic reduction in mortality. A significant number of patients with DCM present an impressive response to pharmacological and non-pharmacological therapy in terms of left ventricular reverse remodeling (reduction in ventricular size with improvement of systolic function), which confers a more favorable prognosis in the long term. However, the identification of patients with an increased likelihood of improvement after therapeutic optimization remains a challenging issue; in particular the assessment of arrhythmic risk carries important implications. Finally, the long-term follow-up of patients showing a significant left ventricular functional recovery under optimal treatment is still poorly known. Hence, the aim of the present review is to provide an insight into the clinical evolution/long-term follow-up of DCM, which should be actually considered a dynamic process rather than a static and chronic disease. Left ventricular reverse remodeling should be considered a key therapeutic goal, mostly associated with a long-standing recovery, but cannot be considered the expression of permanent "healing", confirming the need for a systematic and careful follow-up over time in this setting.
Topics: Cardiomyopathy, Dilated; Disease Progression; Early Diagnosis; Follow-Up Studies; Humans; Incidence; Italy; Magnetic Resonance Imaging; Mass Screening; Predictive Value of Tests; Prevalence; Prognosis; Sensitivity and Specificity; Severity of Illness Index; Ventricular Remodeling
PubMed: 26901255
DOI: 10.1714/2140.23184 -
Journal of the American College of... Jun 2021
Topics: Cardiomyopathy, Dilated; Death, Sudden, Cardiac; Defibrillators, Implantable; Humans; Risk Assessment
PubMed: 34112318
DOI: 10.1016/j.jacc.2021.04.031 -
Zeitschrift Fur Kardiologie 2001Among the cardiomyopathies,--dilated cardiomyopathy (dcm), hypertrophic cardiomyopathy, restrictive cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy--,... (Comparative Study)
Comparative Study Review
Among the cardiomyopathies,--dilated cardiomyopathy (dcm), hypertrophic cardiomyopathy, restrictive cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy--, dcm is the most frequent entity. Its prevalence in the United States amounts to 36 cases per 100,000 inhabitants, men being almost 3-fold more involved than women. The etiology of dcm is very heterogenous; 50% of the cases are due to idiopathic dcm whereas the other half comprises a broad spectrum of various etiologies such as myocarditis, ischemic heart disease, peripartal cardiomyopathy, hypertension, HIV infection, toxic cardiomyopathy and others. In 20 to 30% of the cases of idiopathic dcm a genetic transmission of the disease has been found. Another 20 to 30% of idiopathic dcm are associated with inflammatory and immunological phenomena. Infectious myocarditis with enteroviruses, especially with coxsackie-virus type B has been suggested to be an important trigger for an immune-mediated dcm. In both, familiar dcm and infection with coxsackie-virus B, an impairment of constituents of the myocardial cytoskeleton has been shown. This is regarded as a possible pathogenetic mechanism in the development of dcm.
Topics: Adult; Age Factors; Aged; Cardiomyopathy, Dilated; Female; Genetic Markers; Humans; Incidence; Male; Middle Aged; Risk Factors; Sex Factors
PubMed: 11261335
DOI: 10.1007/s003920170052 -
AACN Clinical Issues in Critical Care... May 1990The nursing care of the patient with dilated cardiomyopathy focuses on (1) improving right and left heart function, i.e., titrating vasoactive drugs to maintain... (Review)
Review
The nursing care of the patient with dilated cardiomyopathy focuses on (1) improving right and left heart function, i.e., titrating vasoactive drugs to maintain acceptable cardiac index with minimum side effects (and/or monitoring the operation of a left ventricular assist device when left heart function is refractory to vasoactive drugs), (2) reducing cardiac filling pressures with diuretics, vasodilators, and/or restriction of dietary sodium, oral and IV fluids, (3) maintaining optimum oxygenation, (4) preventing complications associated with either the disease or treatment, and (5) assisting the patient/family to maintain hope during the often lengthy and crisis-filled wait for a donor heart. The critical care nurse is challenged, often for weeks or months at a time, by the complexity of this patient's physical and emotional needs and functions in a collaborative role with the entire health team in an attempt to maintain both cardiovascular and psychological stability until a donor heart is available.
Topics: Cardiomyopathy, Dilated; Drug Therapy, Combination; Heart-Assist Devices; Humans; Nursing Assessment; Patient Care Planning; Prognosis
PubMed: 2192756
DOI: 10.4037/15597768-1990-1004 -
Circulation. Genomic and Precision... Aug 2023
Topics: Humans; Cardiomyopathy, Dilated; Prevalence; Arrhythmias, Cardiac; Myocardium; Diagnostic Techniques and Procedures; Protein Serine-Threonine Kinases
PubMed: 37325914
DOI: 10.1161/CIRCGEN.123.004207 -
Expert Review of Cardiovascular Therapy 2016Dilated cardiomyopathy (DCM) is a primary heart muscle disease characterized by a progressive dilation and dysfunction of either the left or both ventricles. The...
Dilated cardiomyopathy (DCM) is a primary heart muscle disease characterized by a progressive dilation and dysfunction of either the left or both ventricles. The management of DCM is currently challenging for clinicians. The persistent lack of knowledge about the etiology and pathophysiology of this disease continues to determine important fields of uncertainty in managing this condition. Molecular cardiology and genetics currently represent the most crucial horizon of increasing knowledge. Understanding the mechanisms underlying the disease allows clinicians to treat this disease more effectively and to further improve outcomes of DCM patients through advancements in etiologic characterization, prognostic stratification and individualized therapy. Left ventricular reverse remodeling predicts a lower rate of major cardiac adverse events independently from other factors. Optimized medical treatment and device implantation are pivotal in inducing left ventricular reverse remodeling. Newly identified targets, such as angiotensin-neprilysin inhibition, phosphodiesterase inhibition and calcium sensitizing are important in improving prognosis in patients affected by DCM.
Topics: Cardiomyopathy, Dilated; Heart Ventricles; Humans; Prognosis; Ventricular Remodeling
PubMed: 26606394
DOI: 10.1586/14779072.2016.1125292